Back

G2G Bio draws top 1% traders as monthly obesity-drug race intensifies

Verifying
  • Top 1% South Korean traders by return bought G2G Bio most heavily in late trading on the 16th.
  • G2G Bio closed at 35,350 won on the 15th, up 11.87%.
  • Ascendis Pharma reclaimed once-monthly semaglutide rights after its Novo Nordisk agreement ended.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.